Europska Unija - hrvatski - EMA (European Medicines Agency)

astrazeneca ab - anifrolumab - lupus erythematosus, sistemski - imunosupresivi - saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (sle), despite standard therapy.

Europska Unija - hrvatski - EMA (European Medicines Agency)

astrazeneca ab - budesonide, formoterol fumarate dihydrate, glycopyrronium bromide - plućna bolest, kronična opstruktivna - lijekovi za opstruktivne plućne bolesti dišnih putova, - riltrava aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.

Europska Unija - hrvatski - EMA (European Medicines Agency)

astrazeneca ab - tezepelumab - astma - lijekovi za opstruktivne plućne bolesti dišnih putova, - tezspire is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.

Europska Unija - hrvatski - EMA (European Medicines Agency)

astrazeneca ab - nirsevimab - imuni serumi i homologna, - beyfortus is indicated for the prevention of respiratory syncytial virus (rsv) lower respiratory tract disease in neonates and infants during their first rsv season. beyfortus should be used in accordance with official recommendations.

Europska Unija - hrvatski - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinoma, hepatocellular - antineoplastična sredstva - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

ferring gmbh, wittland 11, kiel, njemačka - budezonid - tableta s produljenim oslobađanjem - 9 mg - urbroj: jedna tableta sadrži 9 mg budezonida

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

cheplapharm arzneimittel gmbh, ziegelhof 24, greifswald, njemačka - kvetiapinfumarat - filmom obložena tableta - 100 mg - urbroj: jedna filmom obložena tableta sadrži 100 mg kvetiapina (u obliku kvetiapinfumarata)

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

cheplapharm arzneimittel gmbh, ziegelhof 24, greifswald, njemačka - kvetiapinfumarat - filmom obložena tableta - 200 mg - urbroj: jedna filmom obložena tableta sadrži 200 mg kvetiapina (u obliku kvetiapinfumarata)

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

cheplapharm arzneimittel gmbh, ziegelhof 24, greifswald, njemačka - kvetiapinfumarat - filmom obložena tableta - 25 mg - urbroj: jedna filmom obložena tableta sadrži 25 mg kvetiapina (u obliku kvetiapinfumarata)

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

cheplapharm arzneimittel gmbh, ziegelhof 24, greifswald, njemačka - kvetiapinfumarat - tableta s produljenim oslobađanjem - 150 mg - urbroj: jedna tableta s produljenim oslobađanjem sadrži 150 mg kvetiapina (u obliku kvetiapinfumarata)